Cyclo (RLsKDK) (TFA)
Cyclo (RLsKDK) (TFA) (BK-1361 (TFA) ) is a specific inhibitor of metalloproteinase ADAM8 with an IC50 value of 182 nM. cyclo (RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer[1].
Product Specifications
Product Name Alternative
BK-1361 (TFA)
UNSPSC
12352209
Target
MMP
Type
Peptides
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cyclo-rlskdk-tfa.html
Purity
99.66
Solubility
H2O : 100 mg/mL (ultrasonic)
Smiles
N=C(N)NCCC[C@@H](C(N[C@H](C(N[C@@H](C(N[C@H]1CCCCN)=O)CO)=O)CC(C)C)=O)NC([C@@H](NC([C@@H](NC1=O)CC(O)=O)=O)CCCCN)=O.O=C(O)C(F)(F)F
Molecular Formula
C33H58F3N11O11
Molecular Weight
841.88
References & Citations
[1]Yim V, et al. Synthesis and biological evaluation of analogues of the potent ADAM8 inhibitor cyclo (RLsKDK) for the treatment of inflammatory diseases and cancer metastasis. Bioorg Med Chem. 2016 Sep 15;24 (18) :4032-4037.|[2]Schlomann U, et al. ADAM8 as a drug target in pancreatic cancer. Nat Commun. 2015 Jan 28;6:6175.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
